Rothia Mucilaginosa (RM) is part of the microbiota of the pharynx and upper respiratory tract. RM is a gram-positive, enveloped, coagulase-negative coccus of the family Micrococcaceae. Clinical manifestations range from mild bronchitis to recurrent pneumonia and lung abscess. It is difficult to determine the clinical significance of this organism in respiratory specimens, therefore, in the diagnosis of pneumonia caused by R. mucilaginosa, bronchoscopy specimens should be cultured. Risk factors associated with Rothia are hematologic malignancies and neutropenia. At present, the importance of Rothia in various pathologies remains unclear due to its difficulty in culture and high potential for contamination at the time of sampling. Although it is an oral microbiota, it has been implicated in pneumonia after being identified in sputum or bronchoalveolar lavage smears and in infectious lesions of the respiratory tract, such as lung abscess and empyema. The challenge of MRI infection in clinical practice is deciding whether it is a real infection or a product of sample contamination. We present the case of a 50-year-old adult patient, without neutropenia, without hematological malignancy, with progressive idiopathic pulmonary fibrosis (IPF) of 1 year of evolution. On admission to the hospital, this person presented signs of respiratory failure, tachycardia, upper rales. auscultation and 85% oxygen saturation, that's why he went through many different studies to diagnose Rothia Mucilaginosa pneumonia.
| Published in | American Journal of Internal Medicine (Volume 11, Issue 2) |
| DOI | 10.11648/j.ajim.20231102.12 |
| Page(s) | 29-31 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2023. Published by Science Publishing Group |
Rothia Mucilaginosa, Pneumonia, Respiratory Tract
| [1] | Sofia Maraki, et al. Rothia mucilaginosa pneumonia. A literature review. Infectious diseases. 2015; 47: 125-129. |
| [2] | Poornima Ramanan, et al. Rothia Bacteremia: a ten year experience at Mayo Clinic, Rochester, Minnesota. J Clin Microbiol. 2014; 52 (9): 3184-9. |
| [3] | Baeza-Martinez C, Zamora-Molina L, García-Sevila R, Gil-Carbonell J, Ramos-Rincon JM, Martin-Serrano C. Rothia mucilaginosa pneumonia in an immunocompetent patient. Arch Bronconeumol. 2014; 50 (11): 493-5. |
| [4] | Trine L. Korsholm, Vera Haahr &Jørgen Prag. Eight cases of lower respiratory tract infection caused by Stomatococcus mucilaginosus. Scand J Infect Dis, 39 (2007), pp. 913-917. |
| [5] | Massimo Fusconi, Cinzia Conti, Armando De Virgilio, Marco de Vincentiis. Paucisymptomatic pneumonia due to Rothia mucilaginosa: case report and literature review. Infez Med, 17 (2009), pp. 100-104. |
| [6] | Eun-Jung Cho, Heungsup Sung, Sook-Ja Park, Mi-Na Kim, and Sang-Oh Lee. Rothia mucilaginosa pneumonia diagnosed by quantitative cultures and intracellular organisms of bronchoalveolar lavage in a lymphoma patient. Ann Lab Med, 33 (2013), pp. 145-149. |
| [7] | D. Gruson, G. Hilbert, A. Pigneux, F. Vargas, O. Guisset, J. Texier, et al. Severe infection caused by Stomatococcus mucilaginosus in a neutropenic patient: Case report and review of the literature. Hematol Cell Ther, 40 (1998), pp. 167-169. |
| [8] | Becker K, von Eiff C. Staphylococcus, Micrococcus and other catalase-positivecocci. En: Becker K, von Eiff C, Bernard KA, Carroll KC, Versalovic J, editores. Manual of Clinical Microbiology. 10th ed. Washington DC: American Society forMicrobiology; 2011. p. 308–30. |
| [9] | Cho EJ, Sung H, Park SJ, Kim MN, Lee SO. Rothia mucilaginosa pneumonia diag-nosed by quantitative cultures and intracellular organisms of bronchoalveolarlavage in a lymphoma patient. Ann Lab Med. 2013; 33: 145–9. |
| [10] | Olivier Lambotte, Thièrry Debord, Charles Soler, René Roué. Pneumonia due to Stomatococcus mucilaginosus in an AIDS patient: Case report and literature review. Clin Microbiol Infect, 5 (1999), pp. 112-114. |
| [11] | D. P. Ascher, C. Zbick, C. White, G. W. Fischer. Infections due to Stomatococcus mucilaginosus: 10cases and review. Rev Infect Dis, 13 (1991), pp. 1048-1052. |
| [12] | P. Fanourgiakis, A. Georgala, M. Vekemans, D. Daneau, C. Heymans, M. Aoun. Bacteremia due to Stomatococcus mucilaginosus in neutropenic patients in the setting of a cancer institute. Clin Microbiol Infect, 9 (2003), pp. 1068-1072. |
| [13] | Chavan RS, Pannaraj PS, Luna RA, Szabo S, et al. Significant morbidity and mortality attributable to rothia mucilaginosa infections in children with hematological malignancies or following hematopoietic stem cell transplantation. Pediatr Hematol Oncol 2013; 30 (5): 445-54. |
| [14] | J. G. Cunniffe, C. Mallia, P. A. Alcock. Stomatococcus mucilaginosus lower respiratory tract infection in a patient with AIDS. J Infect, 29 (1994), pp. 327-330. |
| [15] | Rachel Dena Robertson, Arun Panigrahi, Ritu Cheema. Rothia mucilaginosa bacteremia, meningitis leading to diffuse cerebritis in an adolescent patient undergoing acute myeloid leukemia chemotherapy causing significant morbidity. SAGE Open Med Case Rep. 2021 Dec 8; 9: 2050313X211063745. |
| [16] | Lim YW, Schmieder R, Haynes M, et al. Mechanistic model of Rothia mucilaginosa adaptation toward persistence in the CF lung, based on a genome reconstructed from metagenomic data. PLoS One 2013; 8: e64285. |
| [17] | Charlotte Rigauts, Juliana Aizawa, Steven L. Taylor, Geraint B. Rogers, Matthias Govaerts, Paul Cos, et al. Rothia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease. European Respiratory Journal May 2022, 59 (5) 2101293. |
APA Style
Secchi-Nicolas Nikos Christo, Gomez-Alarcon Angel de Jesus, Barrera-Cruz Ramon Jesus. (2023). Terapeutic Remission of Community Acquired Pneumonia Caused by Rothia Mucilaginosa in an Adult Patient with Idiopathic Pulmonar Fibrosis. American Journal of Internal Medicine, 11(2), 29-31. https://doi.org/10.11648/j.ajim.20231102.12
ACS Style
Secchi-Nicolas Nikos Christo; Gomez-Alarcon Angel de Jesus; Barrera-Cruz Ramon Jesus. Terapeutic Remission of Community Acquired Pneumonia Caused by Rothia Mucilaginosa in an Adult Patient with Idiopathic Pulmonar Fibrosis. Am. J. Intern. Med. 2023, 11(2), 29-31. doi: 10.11648/j.ajim.20231102.12
AMA Style
Secchi-Nicolas Nikos Christo, Gomez-Alarcon Angel de Jesus, Barrera-Cruz Ramon Jesus. Terapeutic Remission of Community Acquired Pneumonia Caused by Rothia Mucilaginosa in an Adult Patient with Idiopathic Pulmonar Fibrosis. Am J Intern Med. 2023;11(2):29-31. doi: 10.11648/j.ajim.20231102.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ajim.20231102.12,
author = {Secchi-Nicolas Nikos Christo and Gomez-Alarcon Angel de Jesus and Barrera-Cruz Ramon Jesus},
title = {Terapeutic Remission of Community Acquired Pneumonia Caused by Rothia Mucilaginosa in an Adult Patient with Idiopathic Pulmonar Fibrosis},
journal = {American Journal of Internal Medicine},
volume = {11},
number = {2},
pages = {29-31},
doi = {10.11648/j.ajim.20231102.12},
url = {https://doi.org/10.11648/j.ajim.20231102.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajim.20231102.12},
abstract = {Rothia Mucilaginosa (RM) is part of the microbiota of the pharynx and upper respiratory tract. RM is a gram-positive, enveloped, coagulase-negative coccus of the family Micrococcaceae. Clinical manifestations range from mild bronchitis to recurrent pneumonia and lung abscess. It is difficult to determine the clinical significance of this organism in respiratory specimens, therefore, in the diagnosis of pneumonia caused by R. mucilaginosa, bronchoscopy specimens should be cultured. Risk factors associated with Rothia are hematologic malignancies and neutropenia. At present, the importance of Rothia in various pathologies remains unclear due to its difficulty in culture and high potential for contamination at the time of sampling. Although it is an oral microbiota, it has been implicated in pneumonia after being identified in sputum or bronchoalveolar lavage smears and in infectious lesions of the respiratory tract, such as lung abscess and empyema. The challenge of MRI infection in clinical practice is deciding whether it is a real infection or a product of sample contamination. We present the case of a 50-year-old adult patient, without neutropenia, without hematological malignancy, with progressive idiopathic pulmonary fibrosis (IPF) of 1 year of evolution. On admission to the hospital, this person presented signs of respiratory failure, tachycardia, upper rales. auscultation and 85% oxygen saturation, that's why he went through many different studies to diagnose Rothia Mucilaginosa pneumonia.},
year = {2023}
}
TY - JOUR T1 - Terapeutic Remission of Community Acquired Pneumonia Caused by Rothia Mucilaginosa in an Adult Patient with Idiopathic Pulmonar Fibrosis AU - Secchi-Nicolas Nikos Christo AU - Gomez-Alarcon Angel de Jesus AU - Barrera-Cruz Ramon Jesus Y1 - 2023/05/10 PY - 2023 N1 - https://doi.org/10.11648/j.ajim.20231102.12 DO - 10.11648/j.ajim.20231102.12 T2 - American Journal of Internal Medicine JF - American Journal of Internal Medicine JO - American Journal of Internal Medicine SP - 29 EP - 31 PB - Science Publishing Group SN - 2330-4324 UR - https://doi.org/10.11648/j.ajim.20231102.12 AB - Rothia Mucilaginosa (RM) is part of the microbiota of the pharynx and upper respiratory tract. RM is a gram-positive, enveloped, coagulase-negative coccus of the family Micrococcaceae. Clinical manifestations range from mild bronchitis to recurrent pneumonia and lung abscess. It is difficult to determine the clinical significance of this organism in respiratory specimens, therefore, in the diagnosis of pneumonia caused by R. mucilaginosa, bronchoscopy specimens should be cultured. Risk factors associated with Rothia are hematologic malignancies and neutropenia. At present, the importance of Rothia in various pathologies remains unclear due to its difficulty in culture and high potential for contamination at the time of sampling. Although it is an oral microbiota, it has been implicated in pneumonia after being identified in sputum or bronchoalveolar lavage smears and in infectious lesions of the respiratory tract, such as lung abscess and empyema. The challenge of MRI infection in clinical practice is deciding whether it is a real infection or a product of sample contamination. We present the case of a 50-year-old adult patient, without neutropenia, without hematological malignancy, with progressive idiopathic pulmonary fibrosis (IPF) of 1 year of evolution. On admission to the hospital, this person presented signs of respiratory failure, tachycardia, upper rales. auscultation and 85% oxygen saturation, that's why he went through many different studies to diagnose Rothia Mucilaginosa pneumonia. VL - 11 IS - 2 ER -
Email: